MRNA Latest Headlines

Looming biosimilar void risks $189B in lost U.S. healthcare savings: report

at seekingalpha.com (Thu, 17-Sep 2:21 PM)

S&P 500 gainers: Today’s top performers ranked by Quant

at seekingalpha.com (Thu, 17-Sep 11:07 AM)

U.S. equities rebound as the Fed delivers its first rate hike in three years

at seekingalpha.com (Thu, 17-Sep 10:30 AM)

10 large and mega-cap U.S. healthcare stocks with the strongest momentum grades

at seekingalpha.com (Thu, 17-Sep 10:00 AM)

These large-cap U.S. stocks have the strongest momentum grades

at seekingalpha.com (Thu, 17-Sep 9:35 AM)

HHS to launch autism research initiative utilizing AI: report

at seekingalpha.com (Wed, 16-Sep 10:35 AM)

Michael Burry joins short-biased fund as senior advisor

at seekingalpha.com (Wed, 16-Sep 9:00 AM)

Goldman Sachs’ long-duration stock basket: SiTime, NIQ lead Quant ratings

at seekingalpha.com (Mon, 14-Sep 6:09 AM)

Goldman rebalances its long duration stock basket

at seekingalpha.com (Sun, 13-Sep 10:12 AM)

Why Selling This Iron Condor in MRNA Makes Sense for a $6.37 Credit

Market Chameleon (Tue, 1-Sep 2:03 PM)

If MRNA Price Stays Inside $140 to $180 Range This Iron Condor Spread Will Yield 52%

Market Chameleon (Wed, 26-Aug 11:27 AM)

How This MRNA Iron Condor Can Net 57% in 8 Days

Market Chameleon (Tue, 25-Aug 10:03 AM)

How This MRNA Iron Condor Can Net 35% in 9 Days

Market Chameleon (Mon, 24-Aug 10:03 AM)

MRNA Bull Put Spread at $0.64 Seems to be Above Fair Value

Market Chameleon (Fri, 21-Aug 12:40 PM)

MRNA Iron Condor Spread Can Make 55% in Next 19 Days

Market Chameleon (Fri, 21-Aug 10:04 AM)

MRNA Iron Condor Can Make 63% in Next 6 Days

Market Chameleon (Thu, 20-Aug 10:08 AM)

MRNA Highlights Transformative Trial Success: First mRNA-Based Cancer Therapy Outperforms Standard-of-Care in Phase 3 Melanoma Study

Market Chameleon (Wed, 19-Aug 10:28 AM)

MRNA Makes History: First Phase 3 mRNA-Based Cancer Therapy Shows Significant Survival Benefits in Melanoma

Market Chameleon (Wed, 19-Aug 7:06 AM)

MRNA Credit Put Spread Appears to be Overvalued at $0.21

Market Chameleon (Wed, 19-Aug 11:12 AM)

Moderna Starts Phase 1 Trial of mRNA-1469 for Bundibugyo Ebolavirus—No Approved Vaccine Exists for This Strain

Market Chameleon (Wed, 5-Aug 7:15 AM)

Moderna Eyes mFLUSIVA Approval as 2026 Outlook Improves with Lower Costs and Key Pipeline Progress

Market Chameleon (Fri, 31-Jul 7:32 AM)

Moderna Launches Phase 1 Trial for mRNA-4200: Aiming to Expand Cancer Immunotherapy with Multi-Antigen Targeting

Market Chameleon (Thu, 16-Jul 7:30 AM)

Moderna Welcomes Former Biogen CFO Michael McDonnell to Board, Signaling Focus on Strategic Growth and Financial Strength

Market Chameleon (Wed, 8-Jul 7:09 AM)

Moderna Expands mRNA Platform Potential with T-Cell Engagers, CAR-T Program, and Cancer Prevention Initiatives

Market Chameleon (Thu, 25-Jun 8:36 AM)

Moderna’s Upcoming Science Day Shines Spotlight on R&D Acceleration Through AI and Robotics

Market Chameleon (Wed, 17-Jun 7:30 AM)